Table 1.

Clinical Characteristics Of The ACC Patients Used In OSacc

ID	Platform	Sample Type	Number Of Samples	Death Events	Median OverAll Survival (Months)	Ages (Years)	Gender (M/F)	Stage (I/II/III/IV)	Reference
GSE10927	GPL570	Primary tumor	24	17	19.02 (8.85–32.83)	7/17 (25.9%/74.1%)	2/11/3/8 (8.3%/45.8%/12.5%/33.3%)	7/17 (25.9%/74.1%)	20
GSE19750	GPL570	Primary tumor	22	18	36.00 (19.35–103.75)	11/11 (50%/50%)	1/7/1/4 (7.7%/53.8/7.7%/30.8%)	11/11 (50%/50%)	8
GSE33371	GPL570	Primary tumor	23	16	15.48 (8.4–61.88)	7/16 (30.4%/69.6%)	2/10/3/8 (8.7%/43.5%/13%/34.8%)	7/16 (30.4%/69.6%)	21
GSE49280	GPL8490	Primary tumor	44	18	51.85 (20.70–112.4)	8/36 (18.2%/81.8%)	–	8/36 (18.2%/81.8%)	22
GSE76019	GPL13158	Primary tumor	34	12#	26.25 (17.59–52.59)	–	10/7/10/7 (29.4%/20.6%/29.4%/20.65)	–	23
GSE76021	GPL96	Primary tumor	20	11*	21.45 (9.21–99.26)	–	5/5/8/2 (25%/25%/40%/10%)	–	23
TCGA	RNAseq	Primary tumor	92	31	31.20 (16.80–58.59)	60/32 (65.2%/34.8%)	9/44/19/18 (10%/48.9%/21.1%/20%)	60/32 (65.2%/34.8%)	24
Total			259	123		93/112 (45.4%/54.6%)	29/84/44/47 (14.3%/41.4%/21.7%/23.2%)	93/112 (45.4%/54.6%)

Notes: ^#EFS event; *PFS event.

Abbreviations: TCGA, TCGA-ACC; NA, not available; M, male; F, female.